AEGR
{"sector":"Healthcare","industry":"Drugs","symbol":"AEGR","company_name":"Aegerion Pharmaceuticals, Inc....","exchange":"NASDAQ"}AEGR Articles
24/7 Wall St. has picked out the biggest movers and winners on Wednesday, particularly biopharma companies making serious runs in the session.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen from Friday, February 26, include American Water Works, Autodesk, Kraft Heinz, Palo Alto Networks, Toyota and Vipshop.
Published:
Last Updated:
Wednesday's top analyst upgrades, downgrades and initiations include Aegerion Pharmaceuticals, Amazon.com, EMC, McDonald's, MetLife, Microsoft, SanDisk and Tyco International.
Published:
Last Updated:
Tuesday’s trading session mixed after having been lower, so the markets are trying to snap the recent losing streak. Many companies are still reporting third quarter earnings, and some of these...
Published:
Last Updated:
In the wake of a reported net loss on disappointing sales of its lead product, Aegerion Pharmaceuticals shares lost a third of their value.
Published:
The big boost to equities following Friday morning’s announcement of additional quantitative easing by the Bank of Japan has been spread widely across most sectors. Still there are several laggards...
Published:
These are the top analyst upgrades and downgrades featured by 24/7 Wall St. for Friday, October 31, 2014.
Published:
24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in hand, while others have pending FDA approval verdicts.
Published:
Bank of America Merrill Lynch is making changes to its Small and Mid Cap Alpha List, a list of companies that have $1 billion to $5 billion market caps at the time of inclusion. Three names were...
Published:
Last Updated:
Merrill Lynch issued a note on Aegerion Pharmaceuticals in the wake of its earnings report that both maintained a Buy rating and maintained its $102 price target. This target implies about 70% upside.
Published:
Last Updated:
The equity research team at Jefferies has come out with a list of their stocks to buy that have been ambushed hard, not only the past two trading days, but since the beginning of the year.
Published:
Biotechnology was an incredible performer in 2013. The analysts at J.P. Morgan think that the huge outperformance may lessen going forward but can stay intact. They think the fundamental backdrop is...
Published:
ThinkstockWith the Federal Reserve reminding investors yesterday that it can raise or lower asset purchases in its quantitative easing program based on the data, all eyes shift to tomorrow’s...
Published:
ThinkstockBiotechnology stocks have had an extremely solid first half of the year. The analysts at Cowen Group point out that expectations are very high and many of the stocks have already made big...
Published:
Secondary offerings matter. They can raise capital for a company and they can help previous investors book profits. They can also cause severe pressure on shares. We have seen either...
Published:
Last Updated: